Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07280221

WEgovy Real World Assessment of Weight Loss in Korea

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Daejeon Endo Internal Medicine Clinic

Daejeon, 35220, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
  • Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
  • Male or female, aged ≥ 19 years at the time of signing the informed consent.

Exclusion criteria

  • Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
  • Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Treatment and study plan

semaglutide

Drug

Semaglutide injection will be self-administered once weekly subcutaneously.

Primary outcomes

  1. Percentage change in body weight

    Time frame: From baseline (week 0) to 24 weeks

    Percent (%)

Secondary outcomes

  1. Absolute change in body weight

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Kilogram (kg)

  2. Percentage change in body weight

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Percent (%)

  3. Achievement in body weight reduction more than or equal to (≥) 5%

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Count of patients

  4. Achievement in body weight reduction ≥ 10%

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Count of patients

  5. Achievement in body weight reduction ≥ 15%

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Count of patients

  6. Achievement in body weight reduction ≥ 20%

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Count of patients

  7. Change in body composition of Lean body mass

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Kg

  8. Change in body composition of Total fat mass

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Kg

  9. Change in body composition of Lean body mass

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Percent (%)

  10. Change in body composition of Total fat mass

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Percent (%)

  11. Change in Body mass index (BMI)

    Time frame: From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks

    Kilogram per meter square (kg/m^2)

  12. Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Count of patients

  13. Change in the proportion of patients by BMI Class II obesity (30 to 34.9 kg/m^2)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Count of patients

  14. Change in the proportion of patients by BMI Class III obesity (≥35 kg/m^2)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Count of patients

  15. Change in waist circumference

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Centimetre (cm)

  16. Change in cardiometabolic parameters - Systolic blood pressure (SBP)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Millimetres of mercury (mmHg)

  17. Change in cardiometabolic parameters - Diastolic blood pressure (DBP)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    mmHg

  18. Change in cardiometabolic parameters - Fasting plasma glucose (FPG)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Milligram per deciliter (mg/dL)

  19. Change in cardiometabolic parameters - Haemoglobin A1c (HbA1c)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    Percent (%)

  20. Change in cardiometabolic parameters - Lipids: total cholesterol (TCh)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    mg/dL

  21. Change in cardiometabolic parameters - Lipids: high-density lipoprotein cholesterol (HDL-C)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    mg/dL

  22. Change in cardiometabolic parameters - Lipids: low-density lipoprotein cholesterol (LDL-C)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    mg/dL

  23. Change in cardiometabolic parameters - Lipids: triglycerides (TG)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    mg/dL

  24. Change in cardiometabolic parameters - Lipids: free fatty acid (FFA)

    Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks

    mg/dL

  25. Change in status of type two diabetes mellitus (T2DM)

    Time frame: Baseline (week 0) to 52 weeks [or end of the study (EOS)]

    Count of patients

  26. Change in status of Hypertension

    Time frame: Baseline (week 0) to 52 weeks (or EOS)

    Count of patients

  27. Change in status of Dyslipidemia

    Time frame: Baseline (week 0) to 52 weeks (or EOS)

    Count of patients

  28. Number of treatment-emergent adverse events (TEAEs)

    Time frame: From baseline (week 0) to 52 weeks (or EOS)

    Count of events

  29. Number of serious TEAEs

    Time frame: From baseline (week 0) to 52 weeks (or EOS)

    Count of events

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 12, 2025
Registry last updated
Dec 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.